Dana-Farber Cancer Institute

https://www.dana-farber.org/

 

Dana-Farber Cancer Institute
D

SITC 2022 on the EO2401 Microbiome Derived Therapeutic Vaccine + Nivo +/- Standard Continuous/Low-Dose Symptom Directed Bev in Recurrent Glioblastoma: Phase 1-2 EOGBM1-18/ROSALIE Study

By Dana-Farber Cancer Institute FEATURING David Reardon
By Dana-Farber Cancer Institute FEATURING David Reardon
30 views
December 10, 2022
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
CNS
27:27
Dana-Farber Cancer Institute

Updates on Glioblastoma

Feat. D. Reardon
13:38
Dana-Farber Cancer Institute

SITC 2022 on the EO2401 Microbiome Derived Therapeutic Vaccine + Niv…

Feat. D. Reardon